Citius Oncology (CTOR) Total Liabilities (2022 - 2026)
Citius Oncology (CTOR) posted quarterly Total Liabilities of $65.4 million for Q1 2026, up 17.27% year-over-year from $55.8 million in Q1 2025, and up 26.9% quarter-over-quarter from $51.6 million in Q4 2025.
Citius Oncology (CTOR) Total Liabilities (2022 - 2026) Analysis & Trends
Citius Oncology (CTOR) has reported Total Liabilities for 5 consecutive years, with $65.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities rose 17.27% year-over-year to $65.4 million; the TTM figure through Mar 2026 stood at $65.4 million (up 17.27% YoY), while the FY2025 annual figure was $56.1 million, up 46.69% from the prior year.
- Total Liabilities improved to $65.4 million in Q1 2026 per CTOR's latest filing, from $51.6 million in the prior quarter.
- Across five years, Total Liabilities topped out at $72.6 million in Q4 2023 and bottomed at $22.2 million in Q3 2023.
- Historically, Total Liabilities has averaged $55.4 million across 5 years, with a median of $55.9 million in 2025.
- On a YoY basis, Total Liabilities climbed as much as 72.21% in 2024 and fell as far as 32.26% in 2024.
- Citius Oncology's Total Liabilities stood at $68.2 million in 2022, then rose by 6.5% to $72.6 million in 2023, then sank by 32.26% to $49.2 million in 2024, then gained by 4.81% to $51.6 million in 2025, then gained by 26.9% to $65.4 million in 2026.
- Business Quant data shows CTOR's Total Liabilities at $65.4 million in Q1 2026, $51.6 million in Q4 2025, and $56.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | -21.66 Bn |
| 2 | Teva Pharmaceutical Industries | 43.07 Bn | 39.42 Bn | 2.15 Bn | 32.10 Bn |
| 3 | Zoetis | 31.53 Bn | 29.85 Bn | 1.05 Bn | 11.93 Bn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 50.85 Bn |
| 5 | United Therapeutics | 22.13 Bn | 19.47 Bn | 683.80 Mn | 819.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 20.78 Bn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 1.67 Bn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 6.97 Bn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | 2.12 Bn |
| 10 | Citius Oncology | 81.99 Mn | 81.99 Mn | 1.00 Mn | 71.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 65.43 Mn |
| Dec 31, 2025 | 51.56 Mn |
| Sep 30, 2025 | 56.08 Mn |
| Jun 30, 2025 | 59.31 Mn |
| Mar 31, 2025 | 55.80 Mn |
| Dec 31, 2024 | 49.19 Mn |
| Sep 30, 2024 | 38.23 Mn |
| Jun 30, 2024 | 49.19 Mn |
| Mar 31, 2024 | 48.68 Mn |
| Dec 31, 2023 | 72.62 Mn |
| Sep 30, 2023 | 22.20 Mn |
| Jun 30, 2023 | 69.85 Mn |
| Mar 31, 2023 | 68.82 Mn |
| Dec 31, 2022 | 68.19 Mn |